STAT
JANUARY 3, 2024
First, a light starts to flash. Then a high-pitched siren starts to blare. Then come the sounds of nearby doors being flung open, and the frantic footsteps of doctors and nurses rushing toward a restroom at the end of a hallway. They’re in a hurry for good reason. These distress signals have a specific meaning: Somebody in the bathroom is overdosing.
Pharmacy Is Right For Me
JANUARY 3, 2024
“How can I make the biggest difference in the lives of others? How can I help the most people?” These questions often cross the minds of students as they navigate the labyrinth of career choices. Dr. Linda Gutierrez-Miller, one such student, embarked on a journey to answer these questions, ultimately choosing a career path that aligns with her goals of making a substantial impact and aiding a diverse range of individuals—clinical pharmacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JANUARY 3, 2024
Mapping the billions of cells that make up the brain is a task mammoth enough to keep hundreds of researchers across continents busy for years. But it’s just one of several ambitious projects the Allen Institute is helping tackle. The nonprofit research institute, based in Seattle, was founded in 2003 by Microsoft co-founder and philanthropist Paul Allen to go after big and basic scientific questions.
PharmaVoice
JANUARY 3, 2024
J&J’s refreshed identity provides insight into how and why pharma companies give themselves a makeover.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JANUARY 3, 2024
Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups. The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.
The Pharmacist
JANUARY 3, 2024
NHS England’s pharmacy workforce group for genomics is seeking to recruit five new pharmacist or pharmacy technician members. Both pharmacy professionals with specialist expertise in genomics and those in the early stages of their career can apply, with expressions of interest to be submitted by 15 January. Applicants must outline any genomic medicine experience, qualifications […] The post Genomics workforce group to recruit new members appeared first on The Pharmacist.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmaphorum
JANUARY 3, 2024
The race for obesity drug assets is becoming more intense as pharmaceutical companies strive to develop effective treatments for weight loss. This article explores the efficacy, potential sales, and market trends in the field of obesity drugs.
STAT
JANUARY 3, 2024
I recently turned 25. I should be taking risks, jet-setting with other Barbies, and flouncing around in tiny tops. Instead, this chronically ill Barbie spent her first four days of 25 in a scene from “Oppenheimer.” On my birthday, I spent nine hours convening with specialists three hours away from home. I contemplated my mortality as we decided which of my overlapping chronic health conditions is the worst so we can make the most of the final year I’m on my parents’ h
pharmaphorum
JANUARY 3, 2024
The UK medicines regulator has launched its mutual recognition framework for authorising medicines in a move that it says will help to bring new drugs to patients in the UK more quickly.
STAT
JANUARY 3, 2024
Hospitals and clinics are expecting a slightly better 2024 compared to last year thanks to a return to mostly in-person care, patients resuming preventive visits and the gradual easing of labor costs and shortages. Still, the evaporation of pandemic-related emergency funding will deal a blow to resource-strained health systems, and leaders say they’ll ramp up tech investments, including in artificial intelligence-based tools.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The Pharmacist
JANUARY 3, 2024
Supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is not expected to return to normal until at least the end of 2024, the government has confirmed. In a patient safety alert published today, the Department of Health and Social Care (DHSC) and NHS England (NHSE) warned prescribers not to switch patients between doses of GLP-1 […] The post Government extends GLP-1 RA shortage warning until end of 2024 appeared first on The Pharmacist.
STAT
JANUARY 3, 2024
Hello, everyone, and how are you today? We are doing fine, thank you, especially given that this is the middle of the week. Perhaps you can relate. Of course, we will forge ahead, as always, since the alternatives appear bleak. This calls for a cup of stimulation and we invite you to join us. Our choice today is cinnamon sticky bun. By the way, we would like to note that, next week, the annual JPM health care gathering takes place — think of it as Woodstock for biopharma dealmakers ȁ
The Pharmacist
JANUARY 3, 2024
The Pharmacist spoke to Royal Pharmaceutical Society (RPS) director for England James Davies towards the end of 2023 to hear what he thinks the future of the profession will look like. As the role of pharmacists and pharmacy technicians continues to evolve, how do you see both professions working well together, and what role does […] The post James Davies: Medicines should be seen as an investment, rather than a cost appeared first on The Pharmacist.
STAT
JANUARY 3, 2024
Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five years, is returning to the fray as chief executive of venture-based Boston startup Kojin Therapeutics. The company, founded in 2019 by a scientific team that includes Harvard research professor Stuart Schreiber, is developing classes of pills that employ ferroptosis biology to attack a wide range of diseases.
European Pharmaceutical Review
JANUARY 3, 2024
Korserdu ® (elacestrant) is the first treatment indicated for ER+, HER2- advanced or metastatic breast cancer tumours with ESR1 mutations. The endocrine therapy has been granted a marketing authorisation by the UK Medicines & Healthcare products Regulatory Agency (MHRA). This represents the first endocrine therapy innovation in nearly 20 years. The small molecule treatment is authorised for postmenopausal women, and men, with oestrogen receptor (ER)-positive, HER2-negative, locally advanced
STAT
JANUARY 3, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello, everyone, and welcome back. Damian here with a look at the year ahead for biotech, plus a long-awaited admission and a remembrance for one of medicine’s true stalwarts.
Express Pharma
JANUARY 3, 2024
Dr Reddy’s Laboratories has acquired MenoLabs business, a women’s health and dietary supplement branded portfolio from Amyris in Amyris’ Chapter 11 sales process. Dr Reddy’s acquired the entire MenoLabs supplements portfolio which includes seven branded products designed to provide health support and address symptoms of perimenopause and menopause.
Outsourcing Pharma
JANUARY 3, 2024
Gilda DâIncerti is CEO and founder of PQE Group, a life science consulting company, and she likes her company to work like a small English village where everyone knows each other.
Pharmaceutical Technology
JANUARY 3, 2024
A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.
pharmaphorum
JANUARY 3, 2024
UK report calls for the mothballed Rosalind Franklin Lab to be repurposed as a manufacturing unit to support clinical trials of bacteriophages as new antimicrobial agents
Pharma Times
JANUARY 3, 2024
NaviCam ProScan is the first AI-assisted reading tool for gastrointestinal bleeding
European Pharmaceutical Review
JANUARY 3, 2024
Outsourcing has become a necessity for many pharmaceutical companies; even the outsourcing of regulatory functions has grown over the past several years and is expected to increase steadily in future. The pharmaceutical regulatory affairs outsourcing market is thus projected to rise from $7 billion in 2022 to $15 billion in 2032, 1 driven by the growing number of clinical trial applications (see Figure 1 ) 2 and product registrations.
Pharma Times
JANUARY 3, 2024
The new hub will be located in the King’s Cross Knowledge Quarter, London
Pharmaceutical Technology
JANUARY 3, 2024
This collaboration comes six years after the German company Boehringer signed two agreements to develop treatments for NASH.
Welltopia Pharmacy
JANUARY 3, 2024
Omega-3s and Pregnancy, Best Practices for Maternal and Fetal Health Overview of the importance of Omega-3s during pregnancy Omega-3 fatty
European Pharmaceutical Review
JANUARY 3, 2024
What are the top trends relating to sterility testing of ATMPs? For me, one of the most promising developments involves the use of the next-generation sequencing-based sterility test (NGSST), which uses whole genome amplification and sequencing followed by microorganism identification with 48 hours. 1 This method removes the requirements for a culture period and has a higher accuracy than other rapid testing methods such as ATP bioluminescence.
Express Pharma
JANUARY 3, 2024
As we stand at the crossroads of innovation and transformation in the pharma sector, the need for visionary leadership has never been more critical. The dynamic landscape of the life sciences industry is evolving at an unprecedented pace, shaped by technological advancements, regulatory shifts, and a growing demand for personalised healthcare solutions.
Pharmaceutical Technology
JANUARY 3, 2024
Novartis will pay Voyager $100m upfront and up to $1.2bn in milestone-based payments and royalties on net sales.
BioPharma Dive
JANUARY 3, 2024
The $650 million fund exceeded Goldman’s target and comes amid cautious optimism that biotech could rebound from a lengthy downturn.
World Pharma News
JANUARY 3, 2024
Could healthy fats found in nuts and fish slow the progression of potentially deadly lung scarring known as pulmonary fibrosis and delay the need for lung transplants? UVA pulmonary researchers looked at the association between blood-plasma levels of omega-3 fatty acids - the heart-healthy fats found in foods such as salmon and flaxseeds - and the progression of pulmonary fibrosis, as well as how long patients could go without needing a transplant.
BioPharma Dive
JANUARY 3, 2024
The hemophilia B therapy, which Pfizer will sell in Canada as Beqvez, is also under review in the U.S., where the FDA expects to make a decision by the second quarter.
Outsourcing Pharma
JANUARY 3, 2024
Heather Stefanski joined NMDP/Be The Match in May, 2021 as vice president, medical services.
Pharmaceutical Technology
JANUARY 3, 2024
The first of a two-part series on therapies that receive an FDA priority review designation dives into how these vouchers incentivise innovation for low-commercial value-diseases.
Drug Patent Watch
JANUARY 3, 2024
Annual Drug Patent Expirations for TASIGNA Tasigna is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. There are seven patents protecting… The post New patent expiration for Novartis drug TASIGNA appeared first on DrugPatentWatch - Make Better Decisions.
Pharmaceutical Business Review
JANUARY 3, 2024
This partnership covers drug-linker technology and CRDMO services right from discovery to commercialisation. WuXi XDC CEO Dr. Jimmy Li said, “IntoCell’s unique drug-linker technologies and our leading, open-access platform are a great combination to enable the fast delivery of pre-clinical candidates, especially in novel ADC programmes. “We are delighted to reach this comprehensive partnership with IntoCell and to forge the capability synergy.
Expert insights. Personalized for you.
359 
Let's personalize your content